

## Tuberculosis Associated Septic Shock

Ida Bagus Putra Narendra, MD\*

Department of Internal Medicine, Wangaya General Hospital, Denpasar, Bali, Indonesia

\*Corresponding author: Ida Bagus Putra Narendra, MD

Department of Internal Medicine, Wangaya General Hospital, Denpasar, Bali, Indonesia

### Abstract

Diagnosing and identifying the underlying disease of septic shock is so difficult, cases of tuberculosis-associated septic shock are extremely rare. A 55-year-old Woman with weakness, nausea, low intake, five episodes of diarrhea, three weeks of coughing, and a positive rapid molecular test result for tuberculosis. The patient had a history of AIDS and was receiving ARV treatment. There had also been a lump in the right neck for a month. A fine needle aspiration biopsy (FNAB) was performed, and the results showed a focus of atypical cells with a background of suppurative chronic inflammation. A physical examination revealed a fever ( $38^{\circ}\text{C}$ ), blood pressure of 78/46 mmHg, and a pulse rate of 110 beats per minute. WBC: 2.60, HB: 7.5, HCT: 23.3, Plt: 353, SGOT/SGPT: 68/8, GDA: 142, BUN/SC: 108/2.6, Na: 141, K: 2.7, Cl: 107 were the results of the laboratory tests. The thorax x-ray revealed a pattern of miliary tuberculosis with a differential diagnosis of the metastatic.

**Keywords:** Tuberculosis, Miliary Tuberculosis, Septic Shock, Metastatic, Sepsis

### 1. Introduction

The body dysregulated reaction to an infection is known as sepsis. Sepsis continues to be the world's leading cause of death. Sepsis was linked to 48.9 million cases, 11 million deaths, and about 20% of all deaths worldwide<sup>17</sup>. Sepsis is most frequently reported to be caused by bacterial infections, with respiratory infections accounting for the largest percentage of cases<sup>6, 9</sup>. The leading cause of death globally is still tuberculosis (TB), with an estimated 2.64 million cases and 1.5 million fatalities annually<sup>5</sup>, 3.4% of TB patients need critical care.

### 2. Case Illustration



A 55-year-old Woman with weakness, nausea, vomiting, shortness of breath and weight loss over the past two months. She had also noted three weeks of productive cough, hemoptysis, night sweat. The patient had a history of AIDS and was receiving ARV treatment. There had also been a lump in the right neck for a month. A fine needle aspiration biopsy (FNAB) was performed, and the results showed a focus of atypical cells with a background of suppurative chronic inflammation. Anemia (Hb: 7.5 g/dL), decreased kidney function (Ketone: 108 g/dL and Creatinine: 2.6 g/dL, Glomerular Filtration Rate: 23 mL/min/1.73 m<sup>2</sup>), blood sugar (142), SGPT/SGOT (8/68), sodium (141), potassium (2.7), chloride (107), leukocytes (11.60 x 10<sup>3</sup>/uL), hemoglobin (7.5 g/dL), and thrombocytes (261 x 10<sup>3</sup>/dL), Albumin (2 g/dL), were among the laboratory results (table 1).

In the emergency department, She was tachycardia 130bpm, hypotensive 80/50 mmHg, tachypneu 38 breaths per minute, and hypoxic 82% on room air requiring a Non-rebreathing face mask. An ECG showed sinus tachycardia, haemoglobin of 7.5 g/dL. A chest X-ray was significant for miliary tuberculosis (Figure 1).

Table 1. Laboratory Result

Examinations	Result
Complete Blood Count	
Leucocytes	11,60 x 10 <sup>3</sup> u/l
Hemoglobin	7.5 g/dL
Hematocrit	30.0%
Platelets	261 x 10 <sup>3</sup> dL
Diff Count	
Neutrophils	73.9%
Lymphocytes	19.2%
Monocytes	6.9%
Mean Corpuscular Volume	87.9
Clinical Chemistry	
Ureum	
Creatinine Serum	108mg/dL
SGOT	2.6 mg/dL
SGPT	68 U/L
Electrolyte	8U/L
Sodium	
Potassium	141 mmol/L
Chloride	2.7 mmol/L
	107 mmol/L
Albumin	2 g/dL



Figure 1: Chest X-ray showed of miliary tuberculosis with metastatic disease being the differential diagnosis.

### 3. Discussion

A type of extra-pulmonary tuberculosis known as "miliary tuberculosis" is caused by the hematogenous spread of the *Mycobacterium tuberculosis* germ. HIV infection is a risk factor for extra-pulmonary tuberculosis (TB); extra-pulmonary TB typically follows HIV infection<sup>24</sup>. Adults are more likely than children to experience TB with septic shock<sup>10</sup>. Immunocompromised cells from tuberculosis can lead to SIRS (Systemic Inflammatory Response Syndrome), multi-organ failure, and sepsis or septic shock<sup>8</sup>. TB continue to spread both lymphatically and hematogenously causing a systemic response. Proinflammatory mediators promote leukocytosis and stimulate the release of other cytokines, all of which act as pyrogens, active WBCs and macrophages, promote chemotaxis, cause immunosuppression, and stimulate both coagulation and fibrinolytic activation<sup>3</sup>. Arachidonic acid and adhesion molecules further cause vascular permeability and migration of aforementioned leukocytes. there is a link between tumor necrosis factor-alpha (TNF-alpha) and activation of the complement pathway, which further enhances neutrophil trafficking and inflammation<sup>11</sup>. This leads to tissue ischemia, cytopathic injury, and increased programmed cell death, eventually resulting in widespread multi-organ damage<sup>4</sup>. The rearrangement and distribution of intravascular fluid, inhibition of vasopressin release, and upregulation of vasoactive mediators such as nitric oxide result in hypotension or shock. At the level of the lung, endothelial damage in the respiratory vasculature disrupts blood flow and increases microvascular penetrability, leading to interstitial and alveolar pulmonary edema. The edematous fluid protein to plasma protein ratio is nearly 0.95, which is significantly higher than those with cardiogenic pulmonary edema. This proteinaceous fluid destroys pneumocytes which increase surface tension, traps leukocytes, and further damage lung vasculature. Diffuse alveolar damage (DAD) ensues, a significant ventilation/perfusion mismatch occurs, and ARDS develops. when widespread TB-related lung damage occurs, ARDS is hardly reversible, especially when complicated by multi-organ failure.

### Conclusion

In areas where tuberculosis is endemic, in particular, it is still impossible to connect the illness with septic shock. The primary therapeutic management for tuberculosis with septic shock still involves timely diagnosis, fluid resuscitation, administration of inotropes, and appropriate administration of antibiotics, just like it does for any other septic shock. A high degree of suspicion for septic shock and prompt management can save many lives. Physicians should be especially aware of tuberculosis that presents as septic shock in endemic areas. To maximize clinical care, multicentric observational studies are required to determine the prevalence and risk factors for tuberculosis septic shock.

### Acknowledgements

Author would like thank to Department of Internal Medicine, Wangaya General Hospital, Denpasar, Bali Indonesia for guidance and invaluable general support.

*Funding: No funding sources*

*Conflict of interest: None declared*

*Ethical approval: Not required*

## References

1. Abdelreheem Y, Mohammad I, Ashraf E, Heba A. Pulmonary tuberculosis in patients with chronic renal failure at Zagazig University Hospitals. *Egyptian Journal of Chest Diseases and Tuberculosis*. 2014; 63(1): p. 187- 192.
2. Mohammad A, Ajit S, Ayman K. Tuberculosis in end-stage renal disease patients on hemodialysis. *International Society for Hemodialysis*. 2016; 10(4): p. 360- 364
3. Bintliffe OJ, Lee GY, Rahman NM, Maskell NA. The management of benign non-infective pleural effusions. *Eur Respir Rev*. 2016;25:303-316. [PMC free article] [PubMed] [Google Scholar]
4. Delano MJ, Ward PA: The immune system's role in sepsis progression, resolution, and long-term outcome . *Immunol Rev*. 2016, 274:330-53. 10.1111/imr.12499
5. De Backer D, Orbegozo Cortes D, Donadello K, Vincent JL. Pathophysiology of microcirculatory dysfunction and the pathogenesis of septic shock. *Virulence*. 2014 Jan 1;5(1):73-9. doi: 10.4161/viru.26482.
6. Epidemiology of tuberculosis and progress toward meeting global targets — worldwide, 2019. Fukunaga R, Glaziou P, Harris JB, Date A, Floyd K, Kasaeva T. *MMWR Morb Mortal Wkly Rep*. 2021;70:427–430. [PMC free article] [PubMed] [Google Scholar]
7. Ferrer R, Martin-Loeches I, Phillips G, Osborn TM, Townsend S, Dellinger RP, Artigas A, Schorr C, Levy MM. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: Results from a guideline-based performance improvement program. *Crit Care Med*. 2014;42:1749–1755. [PubMed] [Google Scholar]
8. Institute for Health Metrics and Evaluation . The Global Burden of Disease : Generating Evidence, Guiding Policy. [https://www.healthdata.org/sites/default/files/files/policy\\_report/2013/GBD\\_](https://www.healthdata.org/sites/default/files/files/policy_report/2013/GBD_)
9. Kethireddy S, Light RB, Mirzanejad Y, et al.: *Mycobacterium tuberculosis septic shock*. *Chest*. 2013, 144:474-82. 10.1378/chest.12-1286
10. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. *Virulence*. 2014;5(1):1–11.
11. Pavlinac PB, Lokken EM, Walson JL, Richardson BA, Crump JA, John-Stewart GC: *Mycobacterium tuberculosis bacteremia in adults and children: a systematic review and meta-analysis*. *Int J Tuberc Lung Dis*. 2016, 20:895-902. 10.5588/ijtld.15.0773
12. Page MJ, Bester J, Pretorius E: The inflammatory effects of TNF- $\alpha$  and complement component 3 on coagulation. *Sci Rep*. 2018, 8:1812. 10.1038/s41598-018-20220
13. Park EJ, Park MA, Park MJ, Park SY, Lee SH. Corticosteroid therapy for refractory uremic pleurisy. *Ewha Med J*. 2016;39:125-128. [Google Scholar]
14. PENEFR. 7th Report Of Indonesian Renal Registry. 2014.Available from: URL: <http://www.indonesianrenalregistry.org>.
15. Rashid-Farokhi F, Pourdowlat G, Nikoonya MR, et al. Uremic pleuritis in chronic hemodialysis patients. *Hemodial Int*. 2013;17:94-100. [PubMed] [Google Scholar]
16. Ray S, Mukherjee S, Ganguly J, Abhishek K, Mitras S, Kundu S. A cross-sectional prospective study of pleural effusion among cases of chronic kidney disease. *Indian J Chest Dis Allied Sci*. 2013;55:209-213. [PubMed] [Google Scholar]
17. RISKESDAS (2013). Riset Kesehatan Dasar Indonesia 2013. <http://www.depkes.go.id/resources/download/general/HasilRiskesdas2013.pdf>
18. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. *Lancet (London, England)*. 2020;395(10219):200-11.
19. Sanjay G, Manoj K, Chandrakant U. Pleural fluid analysis in pleural effusion patient of chronic kidney disease and non chronic kidney disease: A comparative observational study. *MedPulse – International Medical*
20. Situasi penyakit ginjal kronis.infodatin kementerian kesehatan RI. 2017. ISSN 2442-7659 *Journal*. 2017; 4(1): p. 2348- 1897.
21. Sitifa A, Syaiful A, Mefri Y. Gambaran Klinis Penderita Penyakit Ginjal Kronik yang Menjalani Hemodialisis di RSUP Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*. 2018; 7(1): p. 42-50. <http://www.usrds.org>

22. Ulku A, Makbule A, Dilek E, Nagihan K, Erhan O, Ilim I. Role of the Neutrophil-Lymphocyte Ratio in the Differential Diagnosis of Exudative Pleural Effusion. *Clinical Sci Journal*. 2016; 71(10): p. 611-616.
23. U S Renal Data System, USRDS (2013). Annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD.
24. Venkatesh M, Arun BS, Suresh H, Sagar Reddy SL. A study of respiratory manifestations in chronic kidney disease. *International Journal of Biomedical Research*. 2017;8(2):70-4.
25. WHO Tuberculosis Fact Sheet. 2015 <http://www.who.int/mediacentre/factsheets/fs104/en/> <http://www.who.int/mediacentre/factsheets/fs104/en/> [Ref list]